Blocking the activity of the AnxA2 using LCKLSL hexapeptide can have potential therapeutic implications on inhibiting the pathological processes associated with enhanced plasmin generation in high-grade aggressive BLCA [18,37,38]. The gene discussed is PLG; the disease is bladder transitional cell carcinoma.